Bayer has achieved a significant regulatory milestone with the US Food and Drug Administration (FDA) granting accelerated approval for its…
Read More
GSK Secures US Approval for Jideytro in ROS1-Positive Lung Cancer, Entering Competitive Market
Just days after finalizing a monumental $10.6 billion acquisition of Nuvalent, a move that significantly bolsters its oncology pipeline, GlaxoSmithKline…
Read More
Novo Nordisk Secures European Approval for Oral Wegovy, Bolstering First-Mover Advantage in Obesity Pill Market
Novo Nordisk has solidified its pioneering position in the burgeoning market for oral obesity medications with the European Commission’s marketing…
Read More
MSD Secures Landmark Approval for First Oral PCSK9 Inhibitor, Ushering in New Era for Cholesterol Management and Strategic Diversification
The pharmaceutical landscape has been significantly reshaped with MSD (Merck & Co.) achieving a monumental victory: the US Food and…
Read More
Novartis Fabhalta Receives Traditional FDA Approval for IgAN Treatment
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Novartis for Fabhalta (iptacopan), a groundbreaking oral Factor…
Read More
Akeso Secures NMPA Approval for Gumokimab to Treat Plaque Psoriasis in China
Akeso has announced a significant milestone in its therapeutic pipeline with the National Medical Products Administration (NMPA) of China granting…
Read More
Novo Nordisk’s Wegovy Pill Gains UK Approval Amidst Growing Demand and Competitive Landscape
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Novo Nordisk’s oral semaglutide medication, marketed…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
Datroway Receives FDA Approval for Metastatic Triple-Negative Breast Cancer, Marking a Significant Advancement in Targeted Therapy
The US Food and Drug Administration (FDA) has granted a pivotal approval for Datroway (datopotamab deruxtecan), a novel antibody-drug conjugate…
Read More
Paradigm Health Launches SPIRE Platform to Revolutionize Post-Approval Oncology Research
The landscape of oncology therapeutics is rapidly evolving, with groundbreaking treatments continuously emerging and receiving regulatory approval. However, the journey…
Read More
